Melatonin’s effect is not simply “more sedation.” It can act as a signal that tells the body when biological night is beginning. That is why the same product may be more relevant to a delayed body clock than to sleep difficulty caused by stress, pain, medication, or an irregular schedule.

Timing was part of the treatment in a four-week randomized trial of 307 adults with delayed sleep-wake phase disorder. Taking melatonin one hour before the desired bedtime, together with going to bed at a fixed time, moved sleep onset about 34

The evidence does not identify one effective dose for all adults. In a randomized trial of 170 adults aged 55 and older with primary insomnia, three weeks of 2 mg prolonged-release melatonin improved subjective sleep quality and morning alertness compared with placebo. That result applies to the studied age group, treatment period, and formulation; it does not establish better sleep onset or total sleep time for every adult or product.

A meta-analysis of five randomized trials involving 206 people with Parkinson’s disease found clearer sleep-quality effects in studies using more than 4 mg or immediate-release products. Studies using 4 mg or less and prolonged-release products did not show clear improvement.

Not every controlled trial has found a benefit. In a crossover trial of 64 adults aged 40 to 80 with advanced glaucoma, 5 mg of oral melatonin daily for 30 days did not improve sleep quality, total sleep time, sleep efficiency, awakenings, or daytime sleepiness compared with placebo. Both groups improved on some questionnaires over time, showing why improvement from baseline alone does not demonstrate a treatment effect.

Other positive findings come from narrow clinical settings. A small trial in 40 adults receiving chemotherapy reported improvements in selected subjective sleep measures with 6 mg daily, while a review of postoperative medicines in adults aged 60 and older

Short studies were generally reassuring but cannot settle long-term safety. The three-week prolonged-release trial in older adults reported few, mostly minor adverse effects and found no rebound insomnia or withdrawal after treatment stopped. The single-night patch study reported no adverse events, but it took place in a monitored hospital setting. These findings do not establish safety over months or years.

The human studies reviewed here do not define a universal safe dose or reliable medication-interaction rules. They include people with Parkinson’s disease, glaucoma, cancer, insomnia, or impending surgery, whose health conditions and concurrent treatments differ substantially. A dose

Melatonin’s effect is not simply “more sedation.” It can act as a signal that tells the body when biological night is beginning. That is why the same product may be more relevant to a delayed body clock than to sleep difficulty caused by stress, pain, medication, or an irregular schedule.

Timing was part of the treatment in a four-week randomized trial of 307 adults with delayed sleep-wake phase disorder. Taking melatonin one hour before the desired bedtime, together with going to bed at a fixed time, moved sleep onset about 34

The evidence does not identify one effective dose for all adults. In a randomized trial of 170 adults aged 55 and older with primary insomnia, three weeks of 2 mg prolonged-release melatonin improved subjective sleep quality and morning alertness compared with placebo. That result applies to the studied age group, treatment period, and formulation; it does not establish better sleep onset or total sleep time for every adult or product.

A meta-analysis of five randomized trials involving 206 people with Parkinson’s disease found clearer sleep-quality effects in studies using more than 4 mg or immediate-release products. Studies using 4 mg or less and prolonged-release products did not show clear improvement.

Not every controlled trial has found a benefit. In a crossover trial of 64 adults aged 40 to 80 with advanced glaucoma, 5 mg of oral melatonin daily for 30 days did not improve sleep quality, total sleep time, sleep efficiency, awakenings, or daytime sleepiness compared with placebo. Both groups improved on some questionnaires over time, showing why improvement from baseline alone does not demonstrate a treatment effect.

Other positive findings come from narrow clinical settings. A small trial in 40 adults receiving chemotherapy reported improvements in selected subjective sleep measures with 6 mg daily, while a review of postoperative medicines in adults aged 60 and older

Short studies were generally reassuring but cannot settle long-term safety. The three-week prolonged-release trial in older adults reported few, mostly minor adverse effects and found no rebound insomnia or withdrawal after treatment stopped. The single-night patch study reported no adverse events, but it took place in a monitored hospital setting. These findings do not establish safety over months or years.

The human studies reviewed here do not define a universal safe dose or reliable medication-interaction rules. They include people with Parkinson’s disease, glaucoma, cancer, insomnia, or impending surgery, whose health conditions and concurrent treatments differ substantially. A dose